Champions Oncology, Inc. cash flow statement CSBR

Annual Quarterly

In fiscal 2026, which ended Apr 30, 2026, Champions Oncology, Inc. used $4.5 million of cash from operations, down 160.5% from the year before. It spent $564,000 on capital expenditures. Free cash flow was negative, at -$5.0 million.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line	FY 2027 Jul 31, 2026	FY 2026 Apr 30, 2026	FY 2025 Apr 30, 2025	FY 2024 Apr 30, 2024	FY 2023 Apr 30, 2023	FY 2022 Apr 30, 2022	FY 2021 Apr 30, 2021	FY 2020 Apr 30, 2020	FY 2019 Apr 30, 2019	FY 2018 Apr 30, 2018	FY 2017 Apr 30, 2017
Operating
Depreciation and amortization	1 -10.1%	1 -12.5%	2 -15.8%	2 -9.5%	2 +40.0%	2 +62.2%	1 +12.1%	1 +36.1%	1 +68.3%	0 +114.3%	0 +7.7%
Stock-based compensation	2 +197.2%	1 +89.1%	1 -41.5%	1 +29.4%	1 -5.3%	1 +52.5%	1 -0.3%	1 -5.7%	1 -36.7%	1 -62.3%	3 +2.4%
Operating cash flow	-6 -172.5%	-4 -160.5%	7 +220.4%	-6 -254.5%	4 -38.9%	6 +486.5%	-2 -157.9%	3 +56.0%	2 +251.9%	-1 +56.8%	-3 +55.7%
Investing
Capital expenditures	1 +31.7%	1 +45.0%	0 -53.5%	1 -70.9%	3 +20.5%	2 -27.3%	3 +47.8%	2 +166.2%	1 -32.1%	1 +60.4%	1 +137.9%
Investing cash flow	-1 -26.2%	-1 -38.8%	-0 +53.5%	-1 +70.9%	-3 -20.5%	-2 +24.8%	-3 -42.7%	-2 -166.2%	-1 +32.0%	-1 -60.1%	-1 -137.9%
Financing
Stock buybacks	—	—	0 -100.0%	1 +756.8%	0	—	—	—	—	—	—
Financing cash flow	0 -24.4%	0 -41.8%	0 +132.3%	-1 -4890.9%	0 -94.7%	0 -82.7%	1 -73.0%	4 +267.4%	1 +9153.8%	0 -99.7%	4 +10376.2%
Change in cash
Net change in cash	-6 -180.3%	-5 -168.6%	7 +195.6%	-8 -775.1%	1 -74.3%	4 +218.2%	-4 -171.6%	5 +128.8%	2	—	—
Free cash flow	-6 -184.8%	-5 -172.0%	7 +200.3%	-7 -733.9%	1 -73.3%	4 +182.9%	-5 -824.4%	1 -33.4%	1 +141.9%	-2 +31.9%	-4 +46.4%
Per share
Free cash flow per share	—	-0.36 -174.2%	0.49 +195.3%	-0.51 -733.6%	0.08 -72.0%	0.29 +185.3%	-0.34 -688.7%	0.06 -20.7%	0.07	—	—
Shareholder returns
Returned to shareholders	—	—	0	1	0	—	—	—	—	—	—
Share of free cash flow	—	—	0.00%	—	6.73%	—	—	—	—	—	—
Ratios
Free cash flow margin	-10.12%	-8.47%	12.29%	-13.90%	2.04%	8.38%	-12.09%	2.13%	3.80%	—	—
Capital expenditures to revenue	0.94%	0.95%	0.68%	1.67%	5.33%	4.85%	7.99%	6.91%	3.08%	—	—
Stock-based compensation to revenue	2.96%	2.08%	1.15%	2.23%	1.60%	1.86%	1.46%	1.87%	2.35%	—	—
Cash conversion	—	—	1.57x	—	—	11.86x	-4.64x	—	14.55x	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: CSBR (Nasdaq)
Fiscal year ends: April 30
Incorporated in: DE
Headquarters: Baltimore, MD
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 771856
Former names: CHAMPIONS BIOTECHNOLOGY, INC. (until Mar 30, 2011); CHAMPIONS SPORTS INC (until Feb 16, 2007)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.